Therapeutic Potential of Silver Nanoparticles (AgNPs)

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 597

Special Issue Editor

Chemistry Department and CESAM, University of Aveiro, 3800-724 Aveiro, Portugal
Interests: nanomaterials; biomedical applications; environmental applications
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Silver nanoparticles (AgNPs) have gained significant attention in the field of biomedicine, primarily for their antimicrobial properties. However, these versatile nanoparticles are now emerging as multifaceted therapeutic agents capable of being used to address a wide range of diseases. AgNPs exhibit size- and shape-dependent properties, allowing them to be tailored for specific applications. Their high surface-area-to-volume ratio and active surface enable precise control over surface charge and functionalization, further expanding their utility. Additionally, AgNPs possess localized surface plasmonic resonance, which holds promise for photo-assisted therapies.                  

AgNPs can be synthesized through various methods, with chemical reduction synthesis being the most commonly used. However, the utilization of biological methods and the adoption of green chemistry approaches are on the rise, aligning with sustainability objectives.                  

This Special Issue aims to showcase the latest advancements in the utilization of AgNPs for therapeutic purposes, ranging from traditional antibacterial applications to innovative uses. Thus, we invite authors to submit research articles, reviews, and short communications that explore the preparation and application of AgNPs for therapeutic purposes.

Dr. Goreti Pereira
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • metallic nanostructures
  • plasmonic nanomaterials
  • photothermal therapy
  • photodynamic therapy
  • antimicrobial
  • antioxidant
  • anticancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


22 pages, 4080 KiB  
Anti-Bacterial Activity of Green Synthesised Silver and Zinc Oxide Nanoparticles against Propionibacterium acnes
Pharmaceuticals 2024, 17(2), 255; - 16 Feb 2024
Viewed by 370
Propionibacterium acnes plays a critical role in the development of acne vulgaris. There has been a rise in the number of patients carrying P. acnes strains that are resistant to antibiotics. Thus, alternative anti-microbial agents are required. Zinc oxide (ZnO-NPs) and silver (Ag-NPs) [...] Read more.
Propionibacterium acnes plays a critical role in the development of acne vulgaris. There has been a rise in the number of patients carrying P. acnes strains that are resistant to antibiotics. Thus, alternative anti-microbial agents are required. Zinc oxide (ZnO-NPs) and silver (Ag-NPs) nanoparticles can be used against several antibiotic-resistant bacteria. The impact of Ag-NPs and ZnO-NPs against two clinical strains of P. acnes, P1 and P2, and a reference strain, NCTC747, were investigated in this research. A chemical approach for the green synthesis of Ag-NPs and ZnO-NPs from Peganum harmala was employed. The microtiter plate method was used to examine the effects of NPs on bacterial growth, biofilm development, and biofilm eradication. A broth microdilution process was performed in order to determine minimal inhibitory (MIC) concentrations. Ag-NPs and ZnO-NPs had a spherical shape and average dimensions of 10 and 50 nm, respectively. MIC values for all P. acnes strains for Ag-NPs and ZnO-NPs were 125 µg/mL and 250 µg/mL, respectively. Ag-NP and ZnO-NP concentrations of 3.9- 62.5 µg/mL and 15–62.5 µg/mL significantly inhibited the growth and biofilm formation of all P. acnes strains, respectively. ZnO-NP concentrations of 15–62.5 μg/mL significantly inhibited the growth of NCTC747 and P2 strains. The growth of P1 was impacted by concentrations of 31.25 μg/mL and 62.5 μg/mL. Biofilm formation in the NCTC747 strain was diminished by a ZnO-NP concentration of 15 μg/mL. The clinical strains of P. acnes were only affected by ZnO-NP titres of more than 31.25 μg/mL. Established P. acne biofilm biomass was significantly reduced in all strains at a Ag-NP and ZnO-NP concentration of 62.5 µg/mL. The findings demonstrated that Ag-NPs and ZnO-NPs exert an anti-bacterial effect against P. acnes. Further research is required to determine their potential utility as a treatment option for acne. Full article
(This article belongs to the Special Issue Therapeutic Potential of Silver Nanoparticles (AgNPs))
Show Figures

Figure 1

Back to TopTop